Download Citation
Article Source:
Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity
Jung O,
Soto A,
Wolfe AL,
Mahajan SS
(2025)
Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity.
PLOS ONE 20(8): e0329946.
https://doi.org/10.1371/journal.pone.0329946